Hepatocellular adenoma secondary prevention

	Hepatocellular adenoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hepatocellular adenoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hepatocellular adenoma secondary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hepatocellular adenoma secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hepatocellular adenoma secondary prevention
CDC on Hepatocellular adenoma secondary prevention
Hepatocellular adenoma secondary prevention in the news
Blogs on Hepatocellular adenoma secondary prevention
Directions to Hospitals Treating Hepatocellular adenoma
Risk calculators and risk factors for Hepatocellular adenoma secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Zahir Ali Shaikh, MD [2]

Overview

An annual follow-up with MRI or ultrasound may be scheduled for female patients until menopause.

An annual follow-up with MRI or ultrasound may be scheduled for female patients until menopause, when:^[1]

The adenoma is < 5 cm in diameter
It has regressed to < 5 cm after discontinuation of oral contraceptive medications.